Search clinical trials for: CD19/CD22 CAR-T

Total 1157 results

Hrain Biotechnology Co., Ltd.
Ruijin Hospital

Not yet recruiting

To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.

Acute Lymphoblastic Leukemia

China
Chinese PLA General Hospital

Unknown

A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma

B Cell Lymphoma | B Cell Leukemia

China
Hrain Biotechnology Co., Ltd.
Second Affiliated Hospital of Nanchang University

Recruiting

Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients

Central Nervous System Lymphoma

China
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.

Active, not recruiting

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

China
Beijing Tongren Hospital

Recruiting

CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

B-cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.
Tongji Hospital

Recruiting

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

19 and 22+ B Cell Hematologic Tumors | 19 and 20+ B Cell Hematologic Tumors

China
He Huang
Yake Biotechnology Ltd.

Recruiting

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL

B-Cell Acute Lymphoblastic Leukemia, Adult

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL

B-Cell Acute Lymphoblastic Leukemia, Adult

China
Chongqing Precision Biotech Co., Ltd

Recruiting

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
Southwest Hospital, China

Unknown

the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

Lymphoma, Large B-Cell, Diffuse

China
Chongqing Precision Biotech Co., Ltd

Recruiting

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

B-ALL

China
Chongqing Precision Biotech Co., Ltd

Recruiting

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

B Cell Lymphoma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

CAR

China
The First Affiliated Hospital of Soochow University
Northern Jiangsu Province People's Hospital; The Second People's Hospital of... and other collaborators

Recruiting

CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL

B-cell Acute Lymphoblastic Leukemia

China
Shanghai Longyao Biotechnology Inc., Ltd.
Xuzhou Medical University; Shanghai Jiao Tong University School of Medicine

Unknown

Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma

Recurrent or Refractory B Cell Malignancy

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Lymphoma, B-Cell

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Withdrawn

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Refractory B Acute Lymphoblastic Leukemia | Relapse B Acute Lymphoblastic Leukemia

China
Ruijin Hospital
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma

Lymphoma

China
Beijing Doing Biomedical Co., Ltd.

Not yet recruiting

Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL

Lymphoma | Leukemia

China
Peking Union Medical College Hospital

Unknown

A Study of EXP039 Treatment in Subjects With r/r NHL Subjects

Non-Hodgkin's B-cell Lymphoma

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

B Cell Lymphoma | B Cell Leukemia

China
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children... and other collaborators

Recruiting

4SCAR-T Therapy Post CD19-targeted Immunotherapy

CD19 Negative B-cell Malignancies

China
University of Colorado, Denver

Recruiting

UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1

Acute Lymphoblastic Leukemia | Acute Lymphoid Leukemia

United States
Beijing GoBroad Hospital

Recruiting

Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

Acute Lymphoblastic Leukemia, in Relapse | B-cell Acute Lymphoblastic Leukemia | Refractory Acute Lymphoid Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

Lymphoma | Multiple Myeloma | Acute Lymphoblastic Leukemia

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma

Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma

United States
Chimeric Therapeutics

Recruiting

CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

Glioblastoma Multiforme of Brain

United States
Xinqiao Hospital of Chongqing
Chongqing University Cancer Hospital; 920th Hospital of Joint Logistics Support... and other collaborators

Not yet recruiting

CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
Affiliated Hospital to Academy of Military Medical...

Unknown

Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies

Lymphoma | Leukemia

China
Essen Biotech

Not yet recruiting

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). (BAH241)

Lymphoma, Follicular | Diffuse Large B Cell Lymphoma | Acute Lymphoblastic Leukemia, in Relapse | MCL | Central Nervous System Lymphoma | Acute Lymphoblastic Leukemia, Adult B-Cell | Non-Hodgkin Lymphoma, B-cell

China
Kecellitics Biotech Company Ltd
Hebei Yanda Ludaopei Hospital

Not yet recruiting

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

Lymphoma, B-Cell

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma

Non-hodgkin Lymphoma,B Cell

China
Fujian Medical University

Recruiting

Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma (A-02)

Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive

China
Southwest Hospital, China

Unknown

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Lymphoma | Leukemia

China
First Affiliated Hospital of Zhejiang University

Unknown

An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection

Diffuse Large B Cell Lymphoma

China
Allife Medical Science and Technology Co., Ltd.
Peking University Cancer Hospital & Institute

Unknown

Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Refractory B-Cell Lymphoma
Second Affiliated Hospital, School of Medicine,...

Recruiting

Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma

Relapsed and Refractory B-cell Lymphoma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma,B Cell

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

Adult B Acute Lymphoblastic Leukemia

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis

Vasculitis | Amyloidosis | Autoimmune Hemolytic Anemia | POEMS Syndrome

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Refractory Indolent Adult Non-Hodgkin Lymphoma

China
Miltenyi Biomedicine GmbH

Recruiting

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia Refractory

Germany
Shanghai Unicar-Therapy Bio-medicine Technology...
The First Affiliated Hospital of Soochow University

Recruiting

CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Relapse | CD19 Positive | Refractory

China
Miltenyi Biomedicine GmbH

Not yet recruiting

MB-CART19.1 in Refractory SLE

SLE - Systemic Lupus Erythematosus

Germany
Hrain Biotechnology Co., Ltd.
Second Affiliated Hospital of Nanchang University

Recruiting

To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL

B-cell Acute Lymphoblastic Leukemia

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CAR-T Immunotherapy Targeting CD19- ALL

B-cell Leukemia

China
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients

B-cell Lymphoma

China
Beijing Tsinghua Chang Gung Hospital
China Immunotech Pharmaceuticals Co.Ltd.

Suspended

CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.

B-cell Non-Hodgkin's Lymphoma

China

Search clinical trials for: CD19/CD22 CAR-T

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations